Stock Price, News, Quote and Profile of GENEDX HOLDINGS CORP(NASDAQ:WGS) stock

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

GENEDX HOLDINGS CORP

NASDAQ:WGS (11/22/2024, 4:12:45 PM)

After market: 78.71 0 (0%)

78.71

+6.64 (+9.21%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorHealth Care

GICS IndustryHealth Care Providers & Services

GICS SubIndustry

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Chartmill High Growth Momentum

EPS Q2Q%

Sales Q2Q%

CRS

6 Month249.85%

Overview

Earnings (Last)

Earnings (Next)

Ins Owners

Inst Owners

Market Cap2.16B

PEN/A

Fwd PE159.04

Dividend YieldN/A

Analysts

IPO

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

GeneDx Holdings Corp. is a patient centered health intelligence company. The company is headquartered in Stamford, Connecticut and currently employs 1,000 full-time employees. The company went IPO on 2020-09-04. The firm is focused on delivering personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The firm's segments are GeneDx inclusive of Legacy GeneDx and Legacy Sema4. The GeneDx segment primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing and, to a lesser extent, data and information services. GeneDx utilizes an integrated portfolio of laboratory processes, software tools, and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. GeneDx provides a variety of genetic diagnostic tests, screening solutions, and information. The Legacy Sema4 diagnostics segment provides reproductive and women's health and somatic oncology diagnostic testing and screening products.